Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rostislav Raykov - Chief Executive Officer Adrian Haigh - Chief Operating Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group David Nierengarten - Wedbush Securities Operator Good morning, ladies and gentlemen and welcome to the Fennec Pharmaceuticals Second Quarter 2023 Earnings and Corporate Update Conference Ca ...

财务数据和关键指标变化 - 公司报告了PEDMARK产品销售额1.9百万美元,转化为净产品销售额1.7百万美元 [34] - 一般和行政费用为4.3百万美元,较上年同期增加2.2百万美元 [35] - 研发费用下降1.4百万美元,主要是PEDMARK获批后相关费用转为一般和行政费用或资本化为存货 [36] - 公司新增销售和营销费用2.5百万美元,包括分销、物流、广告等 [37] - 公司GAAP净亏损为6百万美元,每股亏损0.23美元 [38] - 公司现金、现金等价物和投资证券余额为18.4百万美元,包括从Petrichor可转债融资25百万美元 [39] 各条业务线数据和关键指标变化 - 公司产品PEDMARK覆盖了多种实体瘤,包括神经母细胞瘤、中枢神经系统肿瘤、骨肉瘤、生殖细胞瘤等 [14] - 公司产品PEDMARK在不同年龄段患儿中的用量会有所不同,较大患儿用量较高,较小患儿用量较低 [44][45] 各个市场数据和关键指标变化 - 公司在美国市场的PEDMARK商业化取得进展,已在主要学术中心和区域医疗机构实现销售 [21][22] - 公司产品获得广泛和有利的医保报销覆盖,约50%患儿有商业保险,50%有政府医保 [23][24] - 公司产品获得CMS永久J编码,有助于简化报销流程,预计将带来更多患者使用 [24][25] - 部分大型学术中心尚未纳入PEDMARK,需要经过长达一年的处方委员会审批流程 [26][27] 公司战略和发展方向及行业竞争 - 公司商业化策略包括建立PEDMARK作为联合用药的必要补充、降低使用障碍、建立客户服务支持等 [16][17][18][19] - 公司已建立专注于200家儿科医院的销售团队,这些医院占据80%的顺铂使用量 [19] - 公司正在评估欧洲市场的最佳商业化路径,包括独立运营或寻求合作伙伴 [30][31] - 公司产品PEDMARK获得FDA孤儿药资格认定,享有7年市场独占期至2029年 [29] 管理层对经营环境和未来前景的评论 - 公司认为PEDMARK商业化正在稳步推进,第二季度和下半年将加速增长 [27] - 公司有信心通过专注的商业化策略在美国市场获得较高的市场份额 [27] - 公司预计未来12个月内可实现收支平衡 [57] 问答环节重要的提问和回答 问题1 **Chase Knickerbocker 提问** 询问Q4和Q1季度收入增长动力,是否存在库存影响 [42] **Rostislav Raykov 回答** 解释不同患儿用量差异导致季度收入变化,没有库存影响 [43][44][45] 问题2 **Raghuram Selvaraju 提问** 询问早期采用医院的占比及其患者规模,未来R&D和G&A支出预期 [61] **Rostislav Raykov 回答** 说明早期采用医院的患者规模情况,R&D支出预计不超过总支出10%,G&A支出已经合理精简 [64][67][69][70] 问题3 **Naureen Quibria 提问** 询问目前客户复购情况及患者覆盖保险情况 [78] **Rostislav Raykov 回答** 说明通过处方委员会后客户复购情况良好,所有患儿均获得保险报销覆盖 [79][80][83][84]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____ to ____ Commission File Number: 001-32295 FENNEC PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 20-0 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 20-0442384 (State ...

FENNEC PHARMA ● November 2022 | Corporate Presentation www.fennecpharma.com FEN-1321-v3 1 Safe Harbor Statement Except for historical information described in this press release, all other statements are forward-looking. Words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeli ...

FENNEC PHARMA ● May 2022 | Corporate Presentation www.fennecpharma.com Safe Harbor Statement During the course of this presentation, we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing and results of pending or future clinical trials, the actions or potential action of the U.S. Food and Drug Administration (FDA), the status and timing of ongoing research, corporate partnering activities and other factors affec ...

FENNEC PHARMA ● March 2022 | Corporate Presentation www.fennecpharma.com Safe Harbor Statement During the course of this presentation, we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing and results of pending or future clinical trials, the actions or potential action of the U.S. Food and Drug Administration (FDA), the status and timing of ongoing research, corporate partnering activities and other factors aff ...

FENNEC PHARMA ● June 2021 | Corporate Presentation www.fennecpharma.com Safe Harbor Statement During the course of this presentation, we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing and results of pending or future clinical trials, the actions or potential action of the U.S. Food and Drug Administration (FDA), the status and timing of ongoing research, corporate partnering activities and other factors affe ...

FENNEC PHARMA ● August 2020 | Corporate Presentation www.fennecpharma.com Safe Harbor Statement During the course of this presentation, we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing and results of pending or future clinical trials, the actions or potential action of the U.S. Food and Drug Administration (FDA), the status and timing of ongoing research, corporate partnering activities and other factors af ...

| --- | --- | --- | |-------|-------|----------------------------------| | | | | | | | | | | | FENNEC PHARMA ● | | | (200 | September 2019 \| Corporate Deck | | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...